trending Market Intelligence /marketintelligence/en/news-insights/trending/gdrezi1_9fgszxivvcjbzg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Teva's $235M payment verdict for infringing GSK patent gets overturned

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Teva's $235M payment verdict for infringing GSK patent gets overturned

A U.S. District Judge reversed a previous decision that awarded GlaxoSmithKline PLC a payment of about $235 million from Teva Pharmaceutical Industries Ltd. for infringing a GSK patent for its blood pressure medicine Coreg, Reuters reported March 28.

GSK had claimed that Teva added treatment of chronic heart failure to the label of its generic version of Coreg in 2011 when that usage was under patent protection. It also claimed that Teva caused doctors to infringe the patent when it sold the generic version and marketed it as a substitute for Coreg.

Judge Leonard Stark stated that there was no evidence to support the finding that Teva's sales of the generic version caused doctors to infringe the patent, according to the news outlet.

The previous ruling had awarded the British drugmaker $234.1 million in lost profits, $1.4 million in royalties and rejected the Israeli generic drugmaker's assertion that the patent was invalid. Stark did not reverse the previous decision regarding the validity of the patent.

In a statement, GSK expressed its disappointment with the decision and stated that it is reviewing its options, while Teva declined to comment, Reuters reported.

The U.S. Food and Drug Administration had approved Teva's generic version of Coreg, or carvedilol, in 2007.